Refine your search results with filters

Specialty
Additional Specialty
Gender
Years of Experience
Level of Expertise

Last Updated: 02/19/2023

Looking for the best doctor for you?
Start Here
 
 
 
 
Learn about our expert tiers
Learn more
Learn about our doctor expertise tiers.
If you have a rare or serious condition, you may want to seek advice from the best doctor you can find.
In most cases, seeking advice from top-tier doctors may not be necessary.
Elite
  • Global leaders in their field
  • Publish in medical journals frequently
  • Speak at conferences
  • Participate in clinical trials
  • Likely to work with cutting edge treatments
  • Likely to hold leadership positions in their organization
Distinguished
  • Leaders in their field
  • Strong research portfolio
  • Likely to work with cutting edge treatments
  • Likely to be a leader in their field regionally
Advanced
  • Excellent at diagnosing and treating conditions.
  • Treat many patients and have extensive experience in their field.
  • May not publish, speak at conferences, or participate in clinical trials.
Experienced
  • Primarily treat patients rather than focus on research.
  • May be specialists or primary care physicians.
  • Have great experience in diagnosing and treating conditions.
  • Majority of doctors fall within this rating.
Find a second opinion
Find now
Location:
Enter a location
Radius:
Global
3,032 doctors found
Sort By
Elite
Elite
Find a second opinion
Learn about our expert tiers
Elite
Elite
Elite
Elite
Elite
Elite
Elite
Elite
Elite
Elite
Elite
Elite
Distinguished
Distinguished
Distinguished
Distinguished
Distinguished
Distinguished
Showing 1-20 of 3,032

Last Updated: 02/19/2023

HER2-positive breast cancer is a subtype of breast cancer that contains human epidermal growth factor receptor 2 (HER2), which is a protein that increases the growth of cancer cells. One out of five breast cancers contain the HER2 protein. Eighteen-to-twenty percent of invasive breast cancers are HER2-positive, which are more aggressive than other breast cancers, more likely to spread and relapse, and have resulted in a decreased survival rate in the past. While previously considered to be the most aggressive type of breast cancer, HER-2 positive breast cancer can now be treated with new biologic targeted therapies that have significantly improved outcomes. HER2-positive breast cancer is categorized in stages that take into account the diameter of the tumor, whether the cancer has spread to axillary (underarm) lymph nodes, and whether the cancer has spread to other organs, such as the liver, lung, brain and bone. Staging allows for treatment plans that target each patient’s individual breast cancer disease. Early breast cancers are staged based on the following criteria: Stage 0 – Ductal cancer in situ (DCIS), or a noninvasive breast cancer that is limited to the ducts. Stage I (A/B) – Cancer has spread from ducts to the surrounding fatty breast tissue. Tumor is smaller than 2 centimeters and has not spread to lymph nodes. Stage II (IIA/B) – Cancer has spread from ducts to the surrounding fatty breast tissue and may have spread to near lymph nodes. Tumor is between 2-to-5 centimeters wide. Advanced breast cancers are staged based on the following criteria: Stage III (IIIA/B) – The tumor is larger than 5 centimeters, cancer may or may not have spread to lymph nodes, or the tumor is smaller, and cancer has spread to lymph nodes. Stage IV – Metastatic Breast Cancer. Cancer has spread to lymph nodes and other parts of the body, with other organs affected, such as liver, lungs, brain, or bones.

Behind the HER-2 Positive Breast Cancer List

MediFind is the industry authority on identifying the leading medical experts and latest research in order to help patients facing complex health challenges, including HER-2 Positive Breast Cancer, make better health decisions. Leveraging our expertise in natural language processing and machine learning across thousands of diseases, we uncover physicians who are leading authorities on HER-2 Positive Breast Cancer. MediFind identifies these experts using proprietary world-class models that assess over 2.5 million global doctors based on a range of variables, including research leadership, patient volume, peer standing, and connectedness to other experts. Learn more about our methodology by exploring how MediFind works.